CliniGA CRO

CliniGA CRO Blog

Sequencing country start-up through dependencies rather than one target date

Giving every country the same opening date can conceal different preparation pathways in a multinational trial.

Representative research photograph: Sequencing country start-up through dependencies rather than one target date
Photo: The U.S. Food and Drug Administration · License: Public domain · Cropped and resized.
Published
Updated

Giving every country the same opening date can conceal different preparation pathways in a multinational trial. Regulatory assessment, local agreements, product supply and team capacity are interdependent. Country sequencing should establish an executable start-up flow rather than reward whichever country appears fastest on a dashboard.

Decision framework

Identify study-specific dependencies for each country. Separate formal assessment steps from preparation activities controlled by the sponsor. Discuss sequencing using document maturity, site readiness and support-function workload alongside recruitment forecasts. Do not treat an authority decision as a guaranteed outcome before it is available.

Worked example

For example, applications for three countries are prepared close together, but one supply team cannot release three label versions in the same week. A sequencing discussion evaluates capacity and ethically workable alternatives instead of simply branding two countries late. Opening the first country does not establish that the others have met their local conditions.

Implementation checks

  • Link each start-up assumption to the relevant document, supply or resource dependency rather than relying on a single colour indicator.
  • Examine simultaneous country workload for critical teams and identify who owns the prioritisation decision.
  • Record who will assess budget, communication and public-record implications if the country sequence changes.

Acceptance and boundaries

Accept the sequence when teams can explain its rationale while preserving continuing obligations in other countries. The plan does not replace local authorisation or site-release checks. Manage dates with their supporting assumptions and uncertainty instead of presenting them as unconditional commitments.

Frequently asked questions

Should the country with the highest recruitment forecast open first?
That measure alone is insufficient; readiness and practical support capacity also affect the choice.
When should country sequencing be reconsidered?
Update the rationale when a critical dependency, authority outcome or support capacity changes.

Sources

  1. EMA — ICH E6 good clinical practice
  2. European Commission — Clinical trials framework